Počet záznamov: 1
Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial
SYS 0060009 LBL 00000naa^^22^^^^^^^^450 005 20130408175506.7 100 $a 20110316a2011 m y0sloy0103 ba 101 0-
$a eng 102 $a SK 200 1-
$a Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial $f M. E. Gore ... [et al.] 305 $a Lancet. 2010 Feb. 20, 375(9715): 641-8 463 -1
$1 001 sllk_un_cat*0059831 $1 011 $a 1336-8176 $1 200 1 $a Onkológia $v Roč. 6, č. 1 (2011), s. 57 $1 210 $a Bratislava $c SOLEN $d 2011 $1 215 $a s. 4-62 541 1-
$a Interferón alfa-2a proti kombinovanej liečbe s interferónom alfa-2a, interleukínom-2 a fluorouracilom u pacientov s neliečeným metastastázujúcim karcinómom obličiek (MRC RE04/EORTC GU 30012): otvorená randomizovaná štúdia $z slo 606 1-
$3 sllk_un_auth*d002292 $a karcinóm renálnych buniek $x farmakoterapia $2 mesh 606 1-
$3 sllk_un_auth*d009362 $a metastázy nádorové $2 mesh 606 1-
$3 sllk_un_auth*d004359 $a farmakoterapia kombinovaná $2 mesh 606 2-
$3 sllk_un_auth*d016898 $a interferón alfa $x použitie terapeutické $2 mesh 606 2-
$3 sllk_un_auth*d007376 $a interleukín-2 $2 mesh 606 2-
$3 sllk_un_auth*d005472 $a fluorouracil $2 mesh 606 2-
$3 sllk_un_auth*d018572 $a prežívanie bez choroby $2 mesh 608 $3 sllk_un_auth*d004740 $a abstrakt v angličtine $2 mesh 701 -1
$3 sllk_un_auth*p0036375 $a Gore $b Martin $p Rare Cancers Division, The Royal Marsden Hospital, London, U.K. $4 070 701 -1
$3 sllk_un_auth*0019810 $a Griffin $b C. L. $4 070 701 -1
$3 sllk_un_auth*0019811 $a Hancock $b B. $4 070 701 -1
$3 sllk_un_auth*0019812 $a Patel $b P. M. $4 070 701 -1
$3 sllk_un_auth*0019813 $a Pyle $b L. $4 070 701 -1
$3 sllk_un_auth*0019814 $a Aitchison $b M. $4 070 701 -1
$3 sllk_un_auth*0019815 $a James $b N. $4 070 701 -1
$3 sllk_un_auth*p0004075 $a Oliver $b R. T. D. $p Department of Medical Oncology, St. Bartholomew's University Hospital, London, UK $4 070 701 -1
$3 sllk_un_auth*p0050765 $a Mardiak $b Jozef $p 2. onkologická klinika LF UK a NOÚ, Bratislava $4 070 701 -1
$3 sllk_un_auth*0019816 $a Hussain $b T. $4 070 701 -1
$3 sllk_un_auth*0019817 $a Sylvester $b R. $4 070 701 -1
$3 sllk_un_auth*0019818 $a Parmar $b M. K. $4 070 701 -1
$3 sllk_un_auth*0019819 $a Royston $b P. $4 070 701 -1
$3 sllk_un_auth*0019820 $a Mulders $b P. F. $4 070 801 -0
$a SK $b BA006 $c 20110316 $g AACR2
Počet záznamov: 1